Chromatographic and Mass Spectrometry Approaches to Supporting Biologics Development

Importance of the topic

Biotherapeutics such as monoclonal antibodies and antibody–drug conjugates play an increasingly vital role in treating chronic and life-threatening diseases. Precise characterization of these complex molecules is critical to ensure structural consistency, safety, and efficacy across development, manufacturing, and quality-control stages.

Aims and overview

This work reviews chromatographic and mass-spectrometry workflows that support biologics development. It highlights novel UHPLC, LC-MS/MS, QTOF, and MALDI-TOF platforms, along with dedicated informatics, to address challenges in impurity profiling, glycan analysis, peptide mapping, and drug-to-antibody ratio assessment.

Methodology and instrumentation

The study employs multiple analytical approaches:

• UHPLC with an entirely inert flow path (Nexera XS inert) to prevent adsorption and metal interactions.
• High-resolution QTOF mass spectrometry (LCMS-9030) with Micro-ESI interface for microflow analyses of model antibodies.
• Triple-quadrupole LC-MS/MS (LCMS-8060NX) featuring rapid polarity switching and enhanced ion focusing for trace quantitation.
• MALDI-TOF (MALDI-8030) for rapid intact mass and subunit analyses in dual-polarity mode.
• Data processing using LabSolutions, Protein Metrics, Skyline, and MALDI Solutions software for chromatographic and spectral deconvolution.

Main results and discussion

Implementation of the bioinert UHPLC system yielded stable peak shapes and reproducible ATP symmetry and area over multiple injections, demonstrating mitigation of analyte–surface interactions. QTOF analyses provided high-accuracy deconvoluted spectra for NIST reference antibodies and therapeutic mAbs such as Trastuzumab and Bevacizumab. The triple-quad platform enabled sensitive MRM quantification and rapid drug-to-antibody ratio (DAR) determinations. MALDI-TOF workflows facilitated glycan profiling, revealing characteristic N-linked glycoforms on the Fc region, and enabled peptide mapping for complementarity-determining region (CDR) verification.

Benefits and practical applications

The integrated suite of techniques supports critical quality attributes monitoring across bioprocess development, formulation optimization, and final product release. Key advantages include high throughput, minimal sample consumption, robust quantitation at low concentrations, and comprehensive structural elucidation from intact proteins to peptide fragments.

Future trends and possibilities

Emerging directions include coupling high-resolution MS with advanced informatics and machine-learning algorithms for automated interpretation of complex datasets; further reduction of flow rates for enhanced sensitivity; and expansion of multiplexed assays for simultaneous assessment of multiple critical quality attributes.

Conclusion

The combination of bioinert chromatography, sensitive mass spectrometry, and tailored data processing delivers a powerful toolkit for biotherapeutics characterization. These innovations streamline development and QC workflows, ensuring consistent product quality and accelerating timelines for new biologics.